Rexahn Pharmaceuticals, Inc. (REXN)
Stock Price:
$2.42 USD
-0.05 (-2.02%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $2.63 +0.21 (8.68%) Aug 14, 5:44 PM
Key Info
| Market Cap |
9.73M |
| Revenue (ttm) |
1.15M |
| Net Income (ttm) |
-6.88M |
| Shares Out |
4.23M |
| EPS (ttm) |
-2.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$2.42 |
| Previous Close |
$2.47 |
| Change ($) |
-0.05 |
| Change (%) |
-2.02% |
| Day's Open |
2.45 |
| Day's Range |
2.42 - 2.51 |
| Day's Volume |
12,056 |
| 52-Week Range |
1.71 - 3.70 |
More Stats
| Market Cap |
9.73M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
4.23M |
| Float |
3.80M |
| EPS (basic) |
-1.71 |
| EPS (diluted) |
-2.66 |
| FCF / Share |
-1.77 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
14,514 |
| Short Ratio |
3.45 |
| Short % of Float |
2.54% |
| Beta |
0.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.46 |
| PB Ratio |
1.09 |
| Revenue |
1.15M |
| Operating Income |
-7.84M |
| Net Income |
-6.88M |
| Free Cash Flow |
-7.12M |
| Net Cash |
10.83M |
| Net Cash / Share |
2.69 |
| Gross Margin |
n/a |
| Operating Margin |
-681.74% |
| Profit Margin |
-598.20% |
| FCF Margin |
-619.54% |
| ROA |
-31.64% |
| ROE |
-54.20% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.00
Current: $2.42
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -11.22 | -20.54 | -17.35 | -16.41 | -18.26 | -13.27 | -7.98 | -6.58 | -16.13 | -10.31 |
| Net Income | -8.64 | -14.37 | -25.29 | -9.31 | -14.38 | -18.52 | -9.50 | -6.23 | -11.34 | -14.02 |
| Shares Outstanding | 3.96 | 2.74 | 2.28 | 1.81 | 1.52 | 1.47 | 1.07 | 0.81 | 0.78 | 0.66 |
| Earnings Per Share | -2.18 | -5.25 | -11.04 | -5.16 | -9.48 | -13.20 | -8.40 | -7.20 | -14.40 | -21.60 |
| Operating Cash Flow | -10.28 | -18.84 | -15.42 | -13.23 | -17.35 | -11.04 | -7.98 | -6.62 | -15.53 | -6.99 |
| Capital Expenditures | -0.01 | -0.04 | -0.08 | -0.01 | -0.06 | -0.04 | -0.05 | - | -0.02 | -0.01 |
| Free Cash Flow | -10.29 | -18.88 | -15.50 | -13.24 | -17.41 | -11.08 | -8.04 | -6.62 | -15.55 | -6.99 |
| Cash & Equivalents | 12.22 | 14.73 | 26.83 | 20.32 | 23.44 | 32.70 | 18.98 | 14.68 | 13.24 | 15.19 |
| Total Debt | 0.20 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 12.01 | 14.73 | 26.83 | 20.32 | 23.44 | 32.70 | 18.98 | 14.68 | 13.24 | 15.19 |
| Assets | 12.97 | 16.04 | 28.29 | 21.04 | 24.81 | 33.53 | 19.56 | 14.92 | 13.69 | 16.22 |
| Liabilities | 3.01 | 5.48 | 11.52 | 3.99 | 6.03 | 6.95 | 6.93 | 5.39 | 2.98 | 5.82 |
| Book Value | 9.96 | 10.56 | 16.77 | 17.06 | 18.78 | 26.58 | 12.63 | 9.53 | 10.71 | 10.40 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Rexahn Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Douglas J. Swirsky |
Stock Information
| Ticker Symbol |
REXN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: REXN |
Description
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.